Overview

Bioavailability Study of Enoxaparin Sodium Chemi and Clexane s.c.

Status:
Completed
Trial end date:
2014-12-05
Target enrollment:
Participant gender:
Summary
- The primary objective of the trial is to assess the single-dose relative bioavailability of Chemi Enoxaparin (80 mg/0.8 mL) and Clexane® (80 mg/0.8 mL) administered by subcutaneous (s.c.) injection, under fasting conditions in healthy volunteers. - The secondary objective of the trial is to assess safety and tolerability of Chemi Enoxaparin (80 mg/0.8 mL) and Clexane® (80 mg/0.8 mL) administered by s.c. injection, under fasting conditions in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Chemi S.p.A.
Treatments:
Enoxaparin
Enoxaparin sodium